Nick Pavlakis

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

Nico van Zandwijk, Nick Pavlakis, Steven Kao et al. · The Lancet Oncology · 2017 · 681 citations

Dose-escalation Study, Glioma, Medicine +8

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 543 citations · Full text

Cobimetinib Versus Regorafenib, Oncology, Medicine +10

Ado-Trastuzumab Emtansine for Patients With <i>HER2</i>-Mutant Lung Cancers: Results From a Phase II Basket Trial

Bob T. Li, Ronglai Shen, Darren J. Buonocore et al. · Journal of Clinical Oncology · 2018 · 541 citations

Tumor Biology, Partial Response Rate, Medicine +14

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

D. Ross Camidge, Rafał Dziadziuszko, Solange Peters et al. · Journal of Thoracic Oncology · 2019 · 488 citations · Full text

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy

Steven Kao, Nick Pavlakis, Rozelle Harvie et al. · Clinical Cancer Research · 2010 · 315 citations · Full text